Cardiovascular research and coordination
01 / Why Cairava
Built from the gapspeople were alreadyclosing by hand.
Cairava grows from years of cardiovascular research and care-coordination experience between hospital discharge and recovery at home.
The product starts with a simple question: what would it take to make that work visible before someone has to chase it down?
Our working thesisManage execution. Do not replace care.
Founding belief
No patient should have to navigate the most vulnerable days after a hospitalization alone.
A synthetic heart-failure transition over seven days: a discharge plan is issued, three items go unresolved with no visible owner, and a transition nurse takes ownership and closes them.
Doris WhitfieldHeart-failure transition · Discharged home
Synthetic patientDay 00Discharge complete
- Medication plan
- Provided
- Cardiology follow-up
- Recommended
- Labs
- Ordered
- Instructions
- Reviewed
Day 01
MedicationPrescription readyBarrier reported
Patient report
The cost is higher than I expected.
Real-world barrier
Day 03
Follow-upCardiology visitNot scheduled
Unfinished coordination
Day 04
Patient question
Who should I call about this?
Signal without visible ownership
?Next ownerNot visible
Day 04
Call placedTransition nurse reaches patientIn progress
- Medication barrier
- Acknowledged
- Cardiology follow-up
- Assigned
- Owner
- Transition nurse
- Closure
- Tracked to ending
Work closed by a person
- 01Start withthe real workflow
- 02Make ownershipvisible
- 03Keep clinical judgmenthuman
- 04Earnevery claim
Manage execution, not care
Virginia
02The origin
Too many essential loops still depend on someone remembering the next call.
Medication, follow-up, education, and access problems emerge between hospital and home. Teams often discover the gap only after it has become harder to resolve.
What the work revealed
Discharge can close an encounter without closing the work that follows it.
The packet is not the workflow
A documented plan still needs sequencing, ownership, evidence, and follow-through.
Patients should not carry the handoff alone
The next right action and a visible way to ask for help should travel with them.
Exceptions need accountable people
Automation can prepare and route; human teams interpret and resolve.
03The product thesis
Cairava does not independently manage heart failure.
It manages execution of the hospital-approved transition plan, with visible ownership and a safe path for bringing exceptions back to the human team.
Review the human decision line→The principles underneath the product
Build trust by making the unfinished work visible.
Cairava is guided by a small set of operating principles intended to keep the product useful, narrow, and accountable as it grows.01
Authority
Preserve the clinical source
The hospital-approved plan and licensed team remain authoritative.
Do not reinterpret care02
Clarity
Design around the next action
Patients should see a finite priority and an obvious way to ask for help.
Reduce cognitive load03
Accountability
Expose unfinished loops
Blocked work stays visible until it reaches an owner or a documented ending.
No silent failure04
Honesty
Name the boundary
Claims, automation limits, evidence state, and production readiness should be understandable.
Earn each capabilityPreserve clinical authority
The EHR and licensed care team remain the source of truth.
Make execution legible
Show each action, owner, due window, barrier, and resolution state.
Earn trust through boundaries
Be explicit about what automation can prepare and what only people can decide.
Review the clinical boundary↗BoundaryThe ambition is not more automation everywhere. It is more dependable follow-through where patients and teams are currently carrying the gap.
Cairava / human signal04Human perspective
Technology earns trust by helping people notice what matters.
Cairava is built around a simple thesis: make the next action clearer, keep unfinished work visible, and leave clinical meaning with the people responsible for care.
01Clarity first02Authority preserved03Trust earned
05How we intend to build
Focused, reviewable, and honest about what is real.
The product should become more capable only as workflow evidence, partner approval, and operating readiness grow.
01
Start contained
Prove one heart-failure pathway before expanding conditions or complexity.
02
Use synthetic validation first
Evaluate the workflow and safety surfaces before production clinical use.
03
Measure operations before outcomes
Begin with ownership, response, workload, and closure.
04
Document every boundary
Keep claims, review state, and production readiness understandable.
06Transparency as a product feature
Visitors should be able to tell what is working, what is intended, and what still needs evidence.
Cairava should communicate progress with the same clarity it expects from the transition workflow itself.
Working versus proposed
Separate validated product behavior from future capability and design intent.
Explore ↗Evidence state
Describe whether a claim comes from workflow testing, partner validation, or an appropriate outcome study.
—Known limitations
Name integration, operational, safety, and adoption constraints before they become surprises.
—Change with accountability
Explain what changed, why it changed, and what review is required before production use.
—07Where we are building
Charlottesville, Virginia.
Cairava is building for the people who carry the transition across settings: patients and caregivers, the care teams accountable for follow-through, and the community hospitals that hold the pathway.
See the design-partner model→01Heart failure first
02Community hospitals
03Hospital to home
04Human-owned decisions
Focused enough to learn carefully. Built to make follow-through visible.
08Questions, clearly answered
A few useful facts about Cairava.
The company, the starting point, and the boundary in plain language.
What is Cairava building?
A hospital-to-home execution layer for a focused, hospital-approved transition workflow.
Why start with heart failure?
Heart failure provides a contained pathway with important medication, follow-up, education, and barrier-resolution work.
Where is Cairava based?
Cairava is based in Charlottesville, Virginia.
10See the workflow together
No patient should navigate the most vulnerable days alone.
See the workflow, review the boundary, and help shape a more accountable handoff.
See the platform →